查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1575457

脑炎药物市场：按治疗类型、疾病类型、给药途径、患者人口统计、最终用户、药物类别和购买类型 - 2025-2030 年全球预测

Encephalitis Treatment Market by Treatment Type, Disease Type, Route of Administration, Patient Demographics, End-User, Drug Class, Mode of Purchase - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年脑炎治疗市值为143.2亿美元，预计到2024年将达到154.9亿美元，复合年增长率为6.59%，到2030年将达到223.9亿美元。

脑炎治疗市场包括脑部发炎，脑部发炎通常由病毒感染引起。治疗包括抗病毒治疗、皮质类固醇和支持性治疗。这是必要的，因为脑炎可能危及生命，并可能导致严重的併发症，如癫痫、认知障碍和神经病变。最终用途主要针对被诊断为脑炎的患者和参与神经照护的医疗保健专业人员。关键的成长要素包括病毒感染疾病发生率的增加、诊断技术的进步以及导致早期诊断的意识的提高。新的潜在机会在于开发更准确、更有效的抗病毒药物和个人化医疗方法，这代表着向基于基因谱和免疫反应的客製化治疗计划的转变。

主要市场统计
基准年[2023] 143.2亿美元
预测年份 [2024] 154.9亿美元
预测年份 [2030] 223.9亿美元
复合年增长率（%） 6.59%

市场洞察凸显了区域流行病学调查对于识别高风险地区的重要性，从而促进了对创新诊断工具和治疗方案的需求。官民合作关係和政府资助也为研发提供了成长机会。然而，挑战包括由于脑炎与其他神经系统疾病的症状重迭而准确诊断脑炎的复杂性，以及与先进诊断程序相关的高成本。此外，低收入地区的意识低和缺乏熟练的医疗保健专业人员也影响了市场的成长。

具有业务成长潜力的创新治疗领域包括开发快速诊断试剂套件和远端医疗解决方案，以扩大偏远地区的覆盖范围并改善早期检测和治疗的可及性。市场的本质是竞争和技术主导，重点是整合人工智慧和机器学习以提高诊断准确性和治疗效果。公司可以透过投资研发伙伴关係、利用数位平台进行教育宣传活动以及提高对脑炎治疗方案的认识来保持竞争力并确保抓住不断变化的市场需求。

市场动态：揭示快速发展的脑炎药物市场的关键市场洞察

供需的动态交互作用正在改变脑炎药物市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助消费行为及其对製造业的影响。

  • 市场驱动因素
    • 脑炎症状的全球流行增加了对有效治疗方案的需求
    • 扩大医疗基础设施和服务可改善脑炎诊断和治疗的机会
    • 医学研究的进步有助于创新解决方案的开发
    • 提高对脑​​炎症状和治疗的认识有助于早期诊断和治疗性介入
  • 市场限制因素
    • 治疗费用上涨
  • 市场机会
    • 对脑炎早期检测和管理的先进诊断工具的需求不断增长
    • 製药公司与学术机构合作创新脑炎治疗方法
    • 增加新解决方案的研发投入
  • 市场挑战
    • 诊断和鑑别诊断的复杂性

波特五力战略工具驾驭脑炎药物市场

波特的五力框架是了解脑炎药物市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解外部对脑炎药物市场的影响

外部宏观环境因素在塑造脑炎治疗药物市场的表现动态中发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解脑炎治疗药物市场的竞争状况

脑炎治疗药物市场的详细市场占有率分析可以对供应商的表现进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵脑炎治疗市场供应商的绩效评估

FPNV 定位矩阵是评估脑炎治疗市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，以确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议，描绘脑炎治疗药物市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，对脑炎治疗药物市场的策略分析至关重要。透过考虑关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 脑炎的盛行率在世界各地不断增加，增加了对有效治疗方法的需求。
      • 扩大医疗基础设施和服务可改善脑炎诊断和治疗的机会
      • 医学研究的进步有助于开发创新的脑炎药物解决方案
      • 提高对脑​​炎症状和治疗的认识有助于早期诊断和治疗性介入
    • 抑制因素
      • 治疗费用高
    • 机会
      • 对脑炎早期检测和管理的先进诊断工具的需求不断增长
      • 製药公司与学术机构合作创新脑炎治疗方法
      • 加脑炎新药方案研发投入
    • 任务
      • 诊断和鑑别诊断的复杂性
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章脑炎治疗药物市场：依治疗类型

  • 抗病毒药物
  • 皮质类固醇
  • 免疫疗法
  • 支持性护理

第七章脑炎治疗药物市场：依疾病类型

  • 自体免疫脑炎
    • 抗NMDA受体脑炎
    • 桥本脑病变
    • 边缘叶脑炎
  • 传染性脑炎
    • 细菌性脑炎
    • 霉菌性脑炎
    • 寄生性脑炎
    • 病毒性脑炎

第八章脑炎治疗药物市场：依给药途径

  • 肌肉注射
  • 静脉
  • 口服

第九章 脑炎治疗药物市场：病人分层

  • 成人用
  • 老年病
  • 小儿科

第十章脑炎治疗药物市场：依最终使用者分类

  • 诊所
  • 家庭护理设置
  • 医院
  • 研究所

第十一章脑炎治疗药物市场：依药物类别

  • 抗病毒药物
    • 阿昔洛韦
    • 膦甲酸
    • 更昔洛韦
  • 皮质类固醇
    • 地塞米松
    • 强的松
  • 免疫球蛋白
    • IVIG

第十二章脑炎治疗药物市场：按购买类型

  • 在商店
  • 处方笺

第13章：北美和南美脑炎治疗药物市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十四章亚太脑炎药物市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十五章欧洲、中东和非洲脑炎治疗药物市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十六章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争场景分析
  • 战略分析和建议
Product Code: MRR-535C629188F4

The Encephalitis Treatment Market was valued at USD 14.32 billion in 2023, expected to reach USD 15.49 billion in 2024, and is projected to grow at a CAGR of 6.59%, to USD 22.39 billion by 2030.

The scope of the encephalitis treatment market involves diagnosing and managing inflammation of the brain, often due to viral infections. Treatment includes antiviral therapies, corticosteroids, and supportive care. The necessity stems from the potentially life-threatening nature of encephalitis, which can result in severe complications such as seizures, cognitive impairments, or neurological deficits. The application scope extends to hospitals, neurology clinics, and research institutions, while end-use is predominantly patients diagnosed with encephalitis and healthcare professionals involved in neurological care. Key growth factors include increased incidence of viral infections, advancements in diagnostic techniques, and heightened awareness leading to early diagnosis. Emerging potential opportunities lie in the development of more precise and efficient antiviral drugs and personalized medicine approaches, indicating a shift towards tailored treatment plans based on genetic profiling and immune response.

KEY MARKET STATISTICS
Base Year [2023] USD 14.32 billion
Estimated Year [2024] USD 15.49 billion
Forecast Year [2030] USD 22.39 billion
CAGR (%) 6.59%

Market insights highlight the importance of regional epidemiological studies to identify high-risk areas, contributing to the demand for innovative diagnostic tools and treatment options. Public-private partnerships and government funding also present growth opportunities in research and development. However, challenges include the complexity in accurately diagnosing encephalitis due to overlapping symptoms with other neurological conditions and the high costs associated with advanced diagnostic procedures. Limitations in terms of limited awareness in low-income areas and the shortage of skilled healthcare professionals also affect market growth.

Innovative areas poised for business growth include the development of rapid diagnostic kits and telemedicine solutions to expand reach in remote areas, improving early detection and treatment accessibility. The market's nature is competitive and technology-driven, with a focus on integrating AI and machine learning to enhance diagnostic accuracy and treatment efficacy. Companies are encouraged to invest in R&D partnerships and leverage digital platforms for educational campaigns to raise awareness about encephalitis treatment options, ensuring they remain competitive and are capturing evolving market demands.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Encephalitis Treatment Market

The Encephalitis Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing prevalence of encephalitis conditions globally increases demand for effective treatment options
    • Expansion of healthcare infrastructure and services enhances access to encephalitis diagnosis and therapies
    • Advancements in medical research contribute to the development of innovative encephalitis treatment solutions
    • Increasing awareness about encephalitis symptoms and treatment boosts early diagnosis and therapeutic interventions
  • Market Restraints
    • High cost of treatment
  • Market Opportunities
    • Growing demand for advanced diagnostic tools for early detection and management of encephalitis
    • Collaborations between pharmaceutical companies and academic institutions for innovative encephalitis therapies
    • Increasing investment in research and development for novel encephalitis treatment solutions
  • Market Challenges
    • Complexity in diagnosis and differentiation

Porter's Five Forces: A Strategic Tool for Navigating the Encephalitis Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Encephalitis Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Encephalitis Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Encephalitis Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Encephalitis Treatment Market

A detailed market share analysis in the Encephalitis Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Encephalitis Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Encephalitis Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Encephalitis Treatment Market

A strategic analysis of the Encephalitis Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Encephalitis Treatment Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Allergan plc, Amgen Inc., AstraZeneca plc, Bayer AG, Biogen Inc., Bristol-Myers Squibb Company, CSL Limited, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Gilead Sciences, Inc., GlaxoSmithKline plc, Johnson & Johnson, Merck & Co., Inc., Novartis International AG, Pfizer Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., and UCB S.A..

Market Segmentation & Coverage

This research report categorizes the Encephalitis Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Treatment Type, market is studied across Antiviral Medication, Corticosteroids, Immunotherapy, and Supportive Care.
  • Based on Disease Type, market is studied across Autoimmune Encephalitis and Infectious Encephalitis. The Autoimmune Encephalitis is further studied across Anti-NMDA Receptor Encephalitis, Hashimoto's Encephalopathy, and Limbic Encephalitis. The Infectious Encephalitis is further studied across Bacterial Encephalitis, Fungal Encephalitis, Parasitic Encephalitis, and Viral Encephalitis.
  • Based on Route of Administration, market is studied across Intramuscular, Intravenous, and Oral.
  • Based on Patient Demographics, market is studied across Adult, Geriatric, and Pediatric.
  • Based on End-User, market is studied across Clinics, Homecare Settings, Hospitals, and Research Institutes.
  • Based on Drug Class, market is studied across Antivirals, Corticosteroids, and Immunoglobulins. The Antivirals is further studied across Acyclovir, Foscarnet, and Ganciclovir. The Corticosteroids is further studied across Dexamethasone and Prednisone. The Immunoglobulins is further studied across IVIG.
  • Based on Mode of Purchase, market is studied across Over-The-Counter and Prescription.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing prevalence of encephalitis conditions globally increases demand for effective treatment options
      • 5.1.1.2. Expansion of healthcare infrastructure and services enhances access to encephalitis diagnosis and therapies
      • 5.1.1.3. Advancements in medical research contribute to the development of innovative encephalitis treatment solutions
      • 5.1.1.4. Increasing awareness about encephalitis symptoms and treatment boosts early diagnosis and therapeutic interventions
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of treatment
    • 5.1.3. Opportunities
      • 5.1.3.1. Growing demand for advanced diagnostic tools for early detection and management of encephalitis
      • 5.1.3.2. Collaborations between pharmaceutical companies and academic institutions for innovative encephalitis therapies
      • 5.1.3.3. Increasing investment in research and development for novel encephalitis treatment solutions
    • 5.1.4. Challenges
      • 5.1.4.1. Complexity in diagnosis and differentiation
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Encephalitis Treatment Market, by Treatment Type

  • 6.1. Introduction
  • 6.2. Antiviral Medication
  • 6.3. Corticosteroids
  • 6.4. Immunotherapy
  • 6.5. Supportive Care

7. Encephalitis Treatment Market, by Disease Type

  • 7.1. Introduction
  • 7.2. Autoimmune Encephalitis
    • 7.2.1. Anti-NMDA Receptor Encephalitis
    • 7.2.2. Hashimoto's Encephalopathy
    • 7.2.3. Limbic Encephalitis
  • 7.3. Infectious Encephalitis
    • 7.3.1. Bacterial Encephalitis
    • 7.3.2. Fungal Encephalitis
    • 7.3.3. Parasitic Encephalitis
    • 7.3.4. Viral Encephalitis

8. Encephalitis Treatment Market, by Route of Administration

  • 8.1. Introduction
  • 8.2. Intramuscular
  • 8.3. Intravenous
  • 8.4. Oral

9. Encephalitis Treatment Market, by Patient Demographics

  • 9.1. Introduction
  • 9.2. Adult
  • 9.3. Geriatric
  • 9.4. Pediatric

10. Encephalitis Treatment Market, by End-User

  • 10.1. Introduction
  • 10.2. Clinics
  • 10.3. Homecare Settings
  • 10.4. Hospitals
  • 10.5. Research Institutes

11. Encephalitis Treatment Market, by Drug Class

  • 11.1. Introduction
  • 11.2. Antivirals
    • 11.2.1. Acyclovir
    • 11.2.2. Foscarnet
    • 11.2.3. Ganciclovir
  • 11.3. Corticosteroids
    • 11.3.1. Dexamethasone
    • 11.3.2. Prednisone
  • 11.4. Immunoglobulins
    • 11.4.1. IVIG

12. Encephalitis Treatment Market, by Mode of Purchase

  • 12.1. Introduction
  • 12.2. Over-The-Counter
  • 12.3. Prescription

13. Americas Encephalitis Treatment Market

  • 13.1. Introduction
  • 13.2. Argentina
  • 13.3. Brazil
  • 13.4. Canada
  • 13.5. Mexico
  • 13.6. United States

14. Asia-Pacific Encephalitis Treatment Market

  • 14.1. Introduction
  • 14.2. Australia
  • 14.3. China
  • 14.4. India
  • 14.5. Indonesia
  • 14.6. Japan
  • 14.7. Malaysia
  • 14.8. Philippines
  • 14.9. Singapore
  • 14.10. South Korea
  • 14.11. Taiwan
  • 14.12. Thailand
  • 14.13. Vietnam

15. Europe, Middle East & Africa Encephalitis Treatment Market

  • 15.1. Introduction
  • 15.2. Denmark
  • 15.3. Egypt
  • 15.4. Finland
  • 15.5. France
  • 15.6. Germany
  • 15.7. Israel
  • 15.8. Italy
  • 15.9. Netherlands
  • 15.10. Nigeria
  • 15.11. Norway
  • 15.12. Poland
  • 15.13. Qatar
  • 15.14. Russia
  • 15.15. Saudi Arabia
  • 15.16. South Africa
  • 15.17. Spain
  • 15.18. Sweden
  • 15.19. Switzerland
  • 15.20. Turkey
  • 15.21. United Arab Emirates
  • 15.22. United Kingdom

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2023
  • 16.2. FPNV Positioning Matrix, 2023
  • 16.3. Competitive Scenario Analysis
  • 16.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Allergan plc
  • 3. Amgen Inc.
  • 4. AstraZeneca plc
  • 5. Bayer AG
  • 6. Biogen Inc.
  • 7. Bristol-Myers Squibb Company
  • 8. CSL Limited
  • 9. Eli Lilly and Company
  • 10. F. Hoffmann-La Roche Ltd
  • 11. Gilead Sciences, Inc.
  • 12. GlaxoSmithKline plc
  • 13. Johnson & Johnson
  • 14. Merck & Co., Inc.
  • 15. Novartis International AG
  • 16. Pfizer Inc.
  • 17. Sanofi S.A.
  • 18. Takeda Pharmaceutical Company Limited
  • 19. Teva Pharmaceutical Industries Ltd.
  • 20. UCB S.A.

LIST OF FIGURES

  • FIGURE 1. ENCEPHALITIS TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. ENCEPHALITIS TREATMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 17. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY MODE OF PURCHASE, 2023 VS 2030 (%)
  • FIGURE 19. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY MODE OF PURCHASE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. AMERICAS ENCEPHALITIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. AMERICAS ENCEPHALITIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. UNITED STATES ENCEPHALITIS TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 23. UNITED STATES ENCEPHALITIS TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. ASIA-PACIFIC ENCEPHALITIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 25. ASIA-PACIFIC ENCEPHALITIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 26. EUROPE, MIDDLE EAST & AFRICA ENCEPHALITIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 27. EUROPE, MIDDLE EAST & AFRICA ENCEPHALITIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 28. ENCEPHALITIS TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 29. ENCEPHALITIS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ENCEPHALITIS TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ENCEPHALITIS TREATMENT MARKET DYNAMICS
  • TABLE 7. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY ANTIVIRAL MEDICATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY AUTOIMMUNE ENCEPHALITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY ANTI-NMDA RECEPTOR ENCEPHALITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY HASHIMOTO'S ENCEPHALOPATHY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY LIMBIC ENCEPHALITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY AUTOIMMUNE ENCEPHALITIS, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY INFECTIOUS ENCEPHALITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY BACTERIAL ENCEPHALITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY FUNGAL ENCEPHALITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY PARASITIC ENCEPHALITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY VIRAL ENCEPHALITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY INFECTIOUS ENCEPHALITIS, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY ANTIVIRALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY ACYCLOVIR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY FOSCARNET, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY GANCICLOVIR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY ANTIVIRALS, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 44. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY DEXAMETHASONE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 45. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY PREDNISONE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 46. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
  • TABLE 47. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY IMMUNOGLOBULINS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 48. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY IVIG, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 49. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
  • TABLE 50. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 51. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY OVER-THE-COUNTER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 52. GLOBAL ENCEPHALITIS TREATMENT MARKET SIZE, BY PRESCRIPTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 53. AMERICAS ENCEPHALITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. AMERICAS ENCEPHALITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. AMERICAS ENCEPHALITIS TREATMENT MARKET SIZE, BY AUTOIMMUNE ENCEPHALITIS, 2018-2030 (USD MILLION)
  • TABLE 56. AMERICAS ENCEPHALITIS TREATMENT MARKET SIZE, BY INFECTIOUS ENCEPHALITIS, 2018-2030 (USD MILLION)
  • TABLE 57. AMERICAS ENCEPHALITIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 58. AMERICAS ENCEPHALITIS TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 59. AMERICAS ENCEPHALITIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 60. AMERICAS ENCEPHALITIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 61. AMERICAS ENCEPHALITIS TREATMENT MARKET SIZE, BY ANTIVIRALS, 2018-2030 (USD MILLION)
  • TABLE 62. AMERICAS ENCEPHALITIS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
  • TABLE 63. AMERICAS ENCEPHALITIS TREATMENT MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
  • TABLE 64. AMERICAS ENCEPHALITIS TREATMENT MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 65. AMERICAS ENCEPHALITIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 66. ARGENTINA ENCEPHALITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. ARGENTINA ENCEPHALITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. ARGENTINA ENCEPHALITIS TREATMENT MARKET SIZE, BY AUTOIMMUNE ENCEPHALITIS, 2018-2030 (USD MILLION)
  • TABLE 69. ARGENTINA ENCEPHALITIS TREATMENT MARKET SIZE, BY INFECTIOUS ENCEPHALITIS, 2018-2030 (USD MILLION)
  • TABLE 70. ARGENTINA ENCEPHALITIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 71. ARGENTINA ENCEPHALITIS TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 72. ARGENTINA ENCEPHALITIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 73. ARGENTINA ENCEPHALITIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 74. ARGENTINA ENCEPHALITIS TREATMENT MARKET SIZE, BY ANTIVIRALS, 2018-2030 (USD MILLION)
  • TABLE 75. ARGENTINA ENCEPHALITIS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
  • TABLE 76. ARGENTINA ENCEPHALITIS TREATMENT MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
  • TABLE 77. ARGENTINA ENCEPHALITIS TREATMENT MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 78. BRAZIL ENCEPHALITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. BRAZIL ENCEPHALITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. BRAZIL ENCEPHALITIS TREATMENT MARKET SIZE, BY AUTOIMMUNE ENCEPHALITIS, 2018-2030 (USD MILLION)
  • TABLE 81. BRAZIL ENCEPHALITIS TREATMENT MARKET SIZE, BY INFECTIOUS ENCEPHALITIS, 2018-2030 (USD MILLION)
  • TABLE 82. BRAZIL ENCEPHALITIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 83. BRAZIL ENCEPHALITIS TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 84. BRAZIL ENCEPHALITIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 85. BRAZIL ENCEPHALITIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 86. BRAZIL ENCEPHALITIS TREATMENT MARKET SIZE, BY ANTIVIRALS, 2018-2030 (USD MILLION)
  • TABLE 87. BRAZIL ENCEPHALITIS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
  • TABLE 88. BRAZIL ENCEPHALITIS TREATMENT MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
  • TABLE 89. BRAZIL ENCEPHALITIS TREATMENT MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 90. CANADA ENCEPHALITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. CANADA ENCEPHALITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. CANADA ENCEPHALITIS TREATMENT MARKET SIZE, BY AUTOIMMUNE ENCEPHALITIS, 2018-2030 (USD MILLION)
  • TABLE 93. CANADA ENCEPHALITIS TREATMENT MARKET SIZE, BY INFECTIOUS ENCEPHALITIS, 2018-2030 (USD MILLION)
  • TABLE 94. CANADA ENCEPHALITIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 95. CANADA ENCEPHALITIS TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 96. CANADA ENCEPHALITIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 97. CANADA ENCEPHALITIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 98. CANADA ENCEPHALITIS TREATMENT MARKET SIZE, BY ANTIVIRALS, 2018-2030 (USD MILLION)
  • TABLE 99. CANADA ENCEPHALITIS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
  • TABLE 100. CANADA ENCEPHALITIS TREATMENT MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
  • TABLE 101. CANADA ENCEPHALITIS TREATMENT MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 102. MEXICO ENCEPHALITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. MEXICO ENCEPHALITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. MEXICO ENCEPHALITIS TREATMENT MARKET SIZE, BY AUTOIMMUNE ENCEPHALITIS, 2018-2030 (USD MILLION)
  • TABLE 105. MEXICO ENCEPHALITIS TREATMENT MARKET SIZE, BY INFECTIOUS ENCEPHALITIS, 2018-2030 (USD MILLION)
  • TABLE 106. MEXICO ENCEPHALITIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 107. MEXICO ENCEPHALITIS TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 108. MEXICO ENCEPHALITIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 109. MEXICO ENCEPHALITIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 110. MEXICO ENCEPHALITIS TREATMENT MARKET SIZE, BY ANTIVIRALS, 2018-2030 (USD MILLION)
  • TABLE 111. MEXICO ENCEPHALITIS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
  • TABLE 112. MEXICO ENCEPHALITIS TREATMENT MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
  • TABLE 113. MEXICO ENCEPHALITIS TREATMENT MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 114. UNITED STATES ENCEPHALITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. UNITED STATES ENCEPHALITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. UNITED STATES ENCEPHALITIS TREATMENT MARKET SIZE, BY AUTOIMMUNE ENCEPHALITIS, 2018-2030 (USD MILLION)
  • TABLE 117. UNITED STATES ENCEPHALITIS TREATMENT MARKET SIZE, BY INFECTIOUS ENCEPHALITIS, 2018-2030 (USD MILLION)
  • TABLE 118. UNITED STATES ENCEPHALITIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 119. UNITED STATES ENCEPHALITIS TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 120. UNITED STATES ENCEPHALITIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 121. UNITED STATES ENCEPHALITIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 122. UNITED STATES ENCEPHALITIS TREATMENT MARKET SIZE, BY ANTIVIRALS, 2018-2030 (USD MILLION)
  • TABLE 123. UNITED STATES ENCEPHALITIS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
  • TABLE 124. UNITED STATES ENCEPHALITIS TREATMENT MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
  • TABLE 125. UNITED STATES ENCEPHALITIS TREATMENT MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 126. UNITED STATES ENCEPHALITIS TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC ENCEPHALITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. ASIA-PACIFIC ENCEPHALITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC ENCEPHALITIS TREATMENT MARKET SIZE, BY AUTOIMMUNE ENCEPHALITIS, 2018-2030 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC ENCEPHALITIS TREATMENT MARKET SIZE, BY INFECTIOUS ENCEPHALITIS, 2018-2030 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC ENCEPHALITIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC ENCEPHALITIS TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC ENCEPHALITIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC ENCEPHALITIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC ENCEPHALITIS TREATMENT MARKET SIZE, BY ANTIVIRALS, 2018-2030 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC ENCEPHALITIS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC ENCEPHALITIS TREATMENT MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC ENCEPHALITIS TREATMENT MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC ENCEPHALITIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 140. AUSTRALIA ENCEPHALITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. AUSTRALIA ENCEPHALITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. AUSTRALIA ENCEPHALITIS TREATMENT MARKET SIZE, BY AUTOIMMUNE ENCEPHALITIS, 2018-2030 (USD MILLION)
  • TABLE 143. AUSTRALIA ENCEPHALITIS TREATMENT MARKET SIZE, BY INFECTIOUS ENCEPHALITIS, 2018-2030 (USD MILLION)
  • TABLE 144. AUSTRALIA ENCEPHALITIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 145. AUSTRALIA ENCEPHALITIS TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 146. AUSTRALIA ENCEPHALITIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 147. AUSTRALIA ENCEPHALITIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 148. AUSTRALIA ENCEPHALITIS TREATMENT MARKET SIZE, BY ANTIVIRALS, 2018-2030 (USD MILLION)
  • TABLE 149. AUSTRALIA ENCEPHALITIS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
  • TABLE 150. AUSTRALIA ENCEPHALITIS TREATMENT MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
  • TABLE 151. AUSTRALIA ENCEPHALITIS TREATMENT MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 152. CHINA ENCEPHALITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 153. CHINA ENCEPHALITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 154. CHINA ENCEPHALITIS TREATMENT MARKET SIZE, BY AUTOIMMUNE ENCEPHALITIS, 2018-2030 (USD MILLION)
  • TABLE 155. CHINA ENCEPHALITIS TREATMENT MARKET SIZE, BY INFECTIOUS ENCEPHALITIS, 2018-2030 (USD MILLION)
  • TABLE 156. CHINA ENCEPHALITIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 157. CHINA ENCEPHALITIS TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 158. CHINA ENCEPHALITIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 159. CHINA ENCEPHALITIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 160. CHINA ENCEPHALITIS TREATMENT MARKET SIZE, BY ANTIVIRALS, 2018-2030 (USD MILLION)
  • TABLE 161. CHINA ENCEPHALITIS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
  • TABLE 162. CHINA ENCEPHALITIS TREATMENT MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
  • TABLE 163. CHINA ENCEPHALITIS TREATMENT MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 164. INDIA ENCEPHALITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 165. INDIA ENCEPHALITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 166. INDIA ENCEPHALITIS TREATMENT MARKET SIZE, BY AUTOIMMUNE ENCEPHALITIS, 2018-2030 (USD MILLION)
  • TABLE 167. INDIA ENCEPHALITIS TREATMENT MARKET SIZE, BY INFECTIOUS ENCEPHALITIS, 2018-2030 (USD MILLION)
  • TABLE 168. INDIA ENCEPHALITIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 169. INDIA ENCEPHALITIS TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 170. INDIA ENCEPHALITIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 171. INDIA ENCEPHALITIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 172. INDIA ENCEPHALITIS TREATMENT MARKET SIZE, BY ANTIVIRALS, 2018-2030 (USD MILLION)
  • TABLE 173. INDIA ENCEPHALITIS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
  • TABLE 174. INDIA ENCEPHALITIS TREATMENT MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
  • TABLE 175. INDIA ENCEPHALITIS TREATMENT MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 176. INDONESIA ENCEPHALITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 177. INDONESIA ENCEPHALITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 178. INDONESIA ENCEPHALITIS TREATMENT MARKET SIZE, BY AUTOIMMUNE ENCEPHALITIS, 2018-2030 (USD MILLION)
  • TABLE 179. INDONESIA ENCEPHALITIS TREATMENT MARKET SIZE, BY INFECTIOUS ENCEPHALITIS, 2018-2030 (USD MILLION)
  • TABLE 180. INDONESIA ENCEPHALITIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 181. INDONESIA ENCEPHALITIS TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 182. INDONESIA ENCEPHALITIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 183. INDONESIA ENCEPHALITIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 184. INDONESIA ENCEPHALITIS TREATMENT MARKET SIZE, BY ANTIVIRALS, 2018-2030 (USD MILLION)
  • TABLE 185. INDONESIA ENCEPHALITIS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
  • TABLE 186. INDONESIA ENCEPHALITIS TREATMENT MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
  • TABLE 187. INDONESIA ENCEPHALITIS TREATMENT MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 188. JAPAN ENCEPHALITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 189. JAPAN ENCEPHALITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 190. JAPAN ENCEPHALITIS TREATMENT MARKET SIZE, BY AUTOIMMUNE ENCEPHALITIS, 2018-2030 (USD MILLION)
  • TABLE 191. JAPAN ENCEPHALITIS TREATMENT MARKET SIZE, BY INFECTIOUS ENCEPHALITIS, 2018-2030 (USD MILLION)
  • TABLE 192. JAPAN ENCEPHALITIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 193. JAPAN ENCEPHALITIS TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 194. JAPAN ENCEPHALITIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 195. JAPAN ENCEPHALITIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 196. JAPAN ENCEPHALITIS TREATMENT MARKET SIZE, BY ANTIVIRALS, 2018-2030 (USD MILLION)
  • TABLE 197. JAPAN ENCEPHALITIS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
  • TABLE 198. JAPAN ENCEPHALITIS TREATMENT MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
  • TABLE 199. JAPAN ENCEPHALITIS TREATMENT MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 200. MALAYSIA ENCEPHALITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 201. MALAYSIA ENCEPHALITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 202. MALAYSIA ENCEPHALITIS TREATMENT MARKET SIZE, BY AUTOIMMUNE ENCEPHALITIS, 2018-2030 (USD MILLION)
  • TABLE 203. MALAYSIA ENCEPHALITIS TREATMENT MARKET SIZE, BY INFECTIOUS ENCEPHALITIS, 2018-2030 (USD MILLION)
  • TABLE 204. MALAYSIA ENCEPHALITIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 205. MALAYSIA ENCEPHALITIS TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 206. MALAYSIA ENCEPHALITIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 207. MALAYSIA ENCEPHALITIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 208. MALAYSIA ENCEPHALITIS TREATMENT MARKET SIZE, BY ANTIVIRALS, 2018-2030 (USD MILLION)
  • TABLE 209. MALAYSIA ENCEPHALITIS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
  • TABLE 210. MALAYSIA ENCEPHALITIS TREATMENT MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
  • TABLE 211. MALAYSIA ENCEPHALITIS TREATMENT MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 212. PHILIPPINES ENCEPHALITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 213. PHILIPPINES ENCEPHALITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 214. PHILIPPINES ENCEPHALITIS TREATMENT MARKET SIZE, BY AUTOIMMUNE ENCEPHALITIS, 2018-2030 (USD MILLION)
  • TABLE 215. PHILIPPINES ENCEPHALITIS TREATMENT MARKET SIZE, BY INFECTIOUS ENCEPHALITIS, 2018-2030 (USD MILLION)
  • TABLE 216. PHILIPPINES ENCEPHALITIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 217. PHILIPPINES ENCEPHALITIS TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 218. PHILIPPINES ENCEPHALITIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 219. PHILIPPINES ENCEPHALITIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 220. PHILIPPINES ENCEPHALITIS TREATMENT MARKET SIZE, BY ANTIVIRALS, 2018-2030 (USD MILLION)
  • TABLE 221. PHILIPPINES ENCEPHALITIS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
  • TABLE 222. PHILIPPINES ENCEPHALITIS TREATMENT MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
  • TABLE 223. PHILIPPINES ENCEPHALITIS TREATMENT MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 224. SINGAPORE ENCEPHALITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 225. SINGAPORE ENCEPHALITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 226. SINGAPORE ENCEPHALITIS TREATMENT MARKET SIZE, BY AUTOIMMUNE ENCEPHALITIS, 2018-2030 (USD MILLION)
  • TABLE 227. SINGAPORE ENCEPHALITIS TREATMENT MARKET SIZE, BY INFECTIOUS ENCEPHALITIS, 2018-2030 (USD MILLION)
  • TABLE 228. SINGAPORE ENCEPHALITIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 229. SINGAPORE ENCEPHALITIS TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 230. SINGAPORE ENCEPHALITIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 231. SINGAPORE ENCEPHALITIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 232. SINGAPORE ENCEPHALITIS TREATMENT MARKET SIZE, BY ANTIVIRALS, 2018-2030 (USD MILLION)
  • TABLE 233. SINGAPORE ENCEPHALITIS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
  • TABLE 234. SINGAPORE ENCEPHALITIS TREATMENT MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
  • TABLE 235. SINGAPORE ENCEPHALITIS TREATMENT MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 236. SOUTH KOREA ENCEPHALITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 237. SOUTH KOREA ENCEPHALITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 238. SOUTH KOREA ENCEPHALITIS TREATMENT MARKET SIZE, BY AUTOIMMUNE ENCEPHALITIS, 2018-2030 (USD MILLION)
  • TABLE 239. SOUTH KOREA ENCEPHALITIS TREATMENT MARKET SIZE, BY INFECTIOUS ENCEPHALITIS, 2018-2030 (USD MILLION)
  • TABLE 240. SOUTH KOREA ENCEPHALITIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 241. SOUTH KOREA ENCEPHALITIS TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 242. SOUTH KOREA ENCEPHALITIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 243. SOUTH KOREA ENCEPHALITIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 244. SOUTH KOREA ENCEPHALITIS TREATMENT MARKET SIZE, BY ANTIVIRALS, 2018-2030 (USD MILLION)
  • TABLE 245. SOUTH KOREA ENCEPHALITIS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
  • TABLE 246. SOUTH KOREA ENCEPHALITIS TREATMENT MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
  • TABLE 247. SOUTH KOREA ENCEPHALITIS TREATMENT MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 248. TAIWAN ENCEPHALITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 249. TAIWAN ENCEPHALITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 250. TAIWAN ENCEPHALITIS TREATMENT MARKET SIZE, BY AUTOIMMUNE ENCEPHALITIS, 2018-2030 (USD MILLION)
  • TABLE 251. TAIWAN ENCEPHALITIS TREATMENT MARKET SIZE, BY INFECTIOUS ENCEPHALITIS, 2018-2030 (USD MILLION)
  • TABLE 252. TAIWAN ENCEPHALITIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 253. TAIWAN ENCEPHALITIS TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 254. TAIWAN ENCEPHALITIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 255. TAIWAN ENCEPHALITIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 256. TAIWAN ENCEPHALITIS TREATMENT MARKET SIZE, BY ANTIVIRALS, 2018-2030 (USD MILLION)
  • TABLE 257. TAIWAN ENCEPHALITIS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
  • TABLE 258. TAIWAN ENCEPHALITIS TREATMENT MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
  • TABLE 259. TAIWAN ENCEPHALITIS TREATMENT MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 260. THAILAND ENCEPHALITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 261. THAILAND ENCEPHALITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 262. THAILAND ENCEPHALITIS TREATMENT MARKET SIZE, BY AUTOIMMUNE ENCEPHALITIS, 2018-2030 (USD MILLION)
  • TABLE 263. THAILAND ENCEPHALITIS TREATMENT MARKET SIZE, BY INFECTIOUS ENCEPHALITIS, 2018-2030 (USD MILLION)
  • TABLE 264. THAILAND ENCEPHALITIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 265. THAILAND ENCEPHALITIS TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 266. THAILAND ENCEPHALITIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 267. THAILAND ENCEPHALITIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 268. THAILAND ENCEPHALITIS TREATMENT MARKET SIZE, BY ANTIVIRALS, 2018-2030 (USD MILLION)
  • TABLE 269. THAILAND ENCEPHALITIS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
  • TABLE 270. THAILAND ENCEPHALITIS TREATMENT MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
  • TABLE 271. THAILAND ENCEPHALITIS TREATMENT MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 272. VIETNAM ENCEPHALITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 273. VIETNAM ENCEPHALITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 274. VIETNAM ENCEPHALITIS TREATMENT MARKET SIZE, BY AUTOIMMUNE ENCEPHALITIS, 2018-2030 (USD MILLION)
  • TABLE 275. VIETNAM ENCEPHALITIS TREATMENT MARKET SIZE, BY INFECTIOUS ENCEPHALITIS, 2018-2030 (USD MILLION)
  • TABLE 276. VIETNAM ENCEPHALITIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 277. VIETNAM ENCEPHALITIS TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 278. VIETNAM ENCEPHALITIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 279. VIETNAM ENCEPHALITIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 280. VIETNAM ENCEPHALITIS TREATMENT MARKET SIZE, BY ANTIVIRALS, 2018-2030 (USD MILLION)
  • TABLE 281. VIETNAM ENCEPHALITIS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
  • TABLE 282. VIETNAM ENCEPHALITIS TREATMENT MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
  • TABLE 283. VIETNAM ENCEPHALITIS TREATMENT MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 284. EUROPE, MIDDLE EAST & AFRICA ENCEPHALITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 285. EUROPE, MIDDLE EAST & AFRICA ENCEPHALITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 286. EUROPE, MIDDLE EAST & AFRICA ENCEPHALITIS TREATMENT MARKET SIZE, BY AUTOIMMUNE ENCEPHALITIS, 2018-2030 (USD MILLION)
  • TABLE 287. EUROPE, MIDDLE EAST & AFRICA ENCEPHALITIS TREATMENT MARKET SIZE, BY INFECTIOUS ENCEPHALITIS, 2018-2030 (USD MILLION)
  • TABLE 288. EUROPE, MIDDLE EAST & AFRICA ENCEPHALITIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 289. EUROPE, MIDDLE EAST & AFRICA ENCEPHALITIS TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 290. EUROPE, MIDDLE EAST & AFRICA ENCEPHALITIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 291. EUROPE, MIDDLE EAST & AFRICA ENCEPHALITIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 292. EUROPE, MIDDLE EAST & AFRICA ENCEPHALITIS TREATMENT MARKET SIZE, BY ANTIVIRALS, 2018-2030 (USD MILLION)
  • TABLE 293. EUROPE, MIDDLE EAST & AFRICA ENCEPHALITIS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
  • TABLE 294. EUROPE, MIDDLE EAST & AFRICA ENCEPHALITIS TREATMENT MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
  • TABLE 295. EUROPE, MIDDLE EAST & AFRICA ENCEPHALITIS TREATMENT MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 296. EUROPE, MIDDLE EAST & AFRICA ENCEPHALITIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 297. DENMARK ENCEPHALITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 298. DENMARK ENCEPHALITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 299. DENMARK ENCEPHALITIS TREATMENT MARKET SIZE, BY AUTOIMMUNE ENCEPHALITIS, 2018-2030 (USD MILLION)
  • TABLE 300. DENMARK ENCEPHALITIS TREATMENT MARKET SIZE, BY INFECTIOUS ENCEPHALITIS, 2018-2030 (USD MILLION)
  • TABLE 301. DENMARK ENCEPHALITIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 302. DENMARK ENCEPHALITIS TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 303. DENMARK ENCEPHALITIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 304. DENMARK ENCEPHALITIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 305. DENMARK ENCEPHALITIS TREATMENT MARKET SIZE, BY ANTIVIRALS, 2018-2030 (USD MILLION)
  • TABLE 306. DENMARK ENCEPHALITIS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
  • TABLE 307. DENMARK ENCEPHALITIS TREATMENT MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
  • TABLE 308. DENMARK ENCEPHALITIS TREATMENT MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 309. EGYPT ENCEPHALITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 310. EGYPT ENCEPHALITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 311. EGYPT ENCEPHALITIS TREATMENT MARKET SIZE, BY AUTOIMMUNE ENCEPHALITIS, 2018-2030 (USD MILLION)
  • TABLE 312. EGYPT ENCEPHALITIS TREATMENT MARKET SIZE, BY INFECTIOUS ENCEPHALITIS, 2018-2030 (USD MILLION)
  • TABLE 313. EGYPT ENCEPHALITIS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 314. EGYPT ENCEPHALITIS TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 315. EGYPT ENCEPHALITIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 316. EGYPT ENCEPHALITIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 317. EGYPT ENCEPHALITIS TREATMENT MARKET SIZE, BY ANTIVIRALS, 2018-2030 (USD MILLION)
  • TABLE 318. EGYPT ENCEPHALITIS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
  • TABLE 319. EGYPT ENCEPHALITIS TREATMENT MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
  • TABLE 320. EGYPT ENCEPHALITIS TREATMENT MARKET SIZE, BY MODE OF PURCHASE, 2018-2030 (USD MILLION)
  • TABLE 321. FINLAND ENCEPHALITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 322. FINLAND ENCEPHALITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 323. FINLAND ENCEPHALITIS TREATMENT MARKET SIZE, BY AUTOIMMUNE ENCEPHALITIS, 2018-2030 (USD MILLION)
  • TABLE 324. FINLAND ENCEPHALITIS TREATMENT MARKET SIZE, BY INFECTIOUS ENC